Printer Friendly
The Free Library
5,677,005 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Drug cuts recurrence of breast cancer.


Letrozole, a drug that derails the body's production of estrogen, reduces breast cancer recurrences in women who have exhausted the usefulness of the anticancer drug anticancer drug

see antineoplastic.

anticancer drug Chemotherapeutic, see there
 tamoxifen tamoxifen (təmŏk`sĭfĕn'), synthetic hormone used in the treatment of breast cancer. Introduced in 1978, tamoxifen is used to prevent recurrences of cancer in women who have already undergone surgery to remove their tumors. , a new drug trial has revealed.

Tamoxifen stops breast cancers in many women by interfering with estrogen's proliferative effect on tumor cells. But taking tamoxifen for more than 5 years provides no additional benefit, compared with going off the drug after that period.

Researchers identified 5,157 post-menopausal women who had taken tamoxifen for about 5 years and randomly assigned them to take either an inert pill or letrozole, which wipes out nearly all estrogen in the body.

The scientists stopped the study when it became clear that the group receiving letrozole had roughly three-fifths as many breast cancer recurrences as did women getting the placebo, says study coauthor Paul E. Goss, a medical oncologist medical oncologist  Oncology An oncologist who diagnoses and treats cancer with chemotherapy, hormones, biologicals, or immunologic agents; the MO becomes a cancer Pt's de facto primary care giver, and coordinates treatment provided by other specialists.  at Princess Margaret Hospital There are several Princess Margaret Hospitals :
  • Princess Margaret Hospital, Hong Kong
  • Princess Margaret Hospital, Toronto
  • Princess Margaret Hospital for Children in Perth
  • Princess Margaret Hospital, Christchurch
 in Toronto. Researchers then offered letrozole to all participants, each of whom had been followed for 2.4 years on average. The report appears in the Nov. 6 New England Journal of Medicine The New England Journal of Medicine (New Engl J Med or NEJM) is an English-language peer-reviewed medical journal published by the Massachusetts Medical Society. It is one of the most popular and widely-read peer-reviewed general medical journals in the world. .

Letrozole disables an enzyme called aromatase, which the body needs to make estrogen. Another aromatase inhibitor aromatase inhibitor
n.
A drug that inhibits tumor growth, especially breast cancer, by inhibiting the enzyme aromatase and thereby lowering estrogen levels in the blood or in tumor tissues.
, the drug anastrozole, is also being tested for cancer-fighting abilities (SN: 11/24/01, p. 327).

Although tamoxifen's anticancer effect levels out at 5 years, there's no question that the drug imparts a residual benefit even after long-term users stop taking it. Indeed, no one knows how long the benefits of tamoxifen or the aromatase inhibitors might linger. That and the question of whether the drugs might interact in good or bad ways when given simultaneously are the topics of several studies now under way.

Letrozole is marketed as Femara by Novartis in New York, which was a sponsor of the newly reported trial.--S.P.
COPYRIGHT 2003 Science Service, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Biomedicine)(Letrozole; Letrozole; Biomedicine
Publication:Science News
Article Type:Brief Article
Geographic Code:1USA
Date:Nov 29, 2003
Words:300
Previous Article:Fill 'er up...with a few tons of wheat.(Earth Science)(Brief Article)
Next Article:Protein triggers nerve connections.(Brain Development)(Brief Article)
Topics:



Related Articles
Drugs give slight edge in breast cancer.
The adjuvant advantage: breast cancer therapies promise a longer life. (Cover Story)
Tamoxifen quandary; promising cancer drug may hide a troubling dark side. (includes related articles)
Studies spark new tamoxifen controversy. (drug linked to endometrial cancer)
Tamoxifen therapy should last 5 years. (risks of uterine cancer may outweigh benefit of Tamoxifen after 5 years)(Biomedicine)(Brief Article)
Drug prevents some cancer, poses risks.(tamoxifen)(Brief Article)
Tamoxifen may not prevent breast cancer.(Brief Article)
Tamoxifen Therapy Should Last 5 Years.(breast cancer therapy)
Enzyme fighter works as well as tamoxifen.(anastrozole shown to be more effective against estrogen-dependent breast cancer than tamoxifen)(Brief...
Women & living with breast cancer today.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles